A Phase 3, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants with Refractory Chronic Inflammatory Demyelinating (CIDP) Polyneuropathy
A Study to Test the Effects and Safety of Riliprubart in People with Chronic CIDP for Which the Usual Treatment Does Not Work
Sponsor: Sanofi US Services
Enrolling: Male and Female Patients
IRB Number: AAAV0943
U.S. Govt. ID: NCT06290128
Contact: Jorge E. Cabrera: / jec2273@cumc.columbia.edu
Additional Study Information: This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must be 18 years old at the time of signing the informed consent.
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have CIPD or possibly meet the CIDP criteria (typical CIDP, motor CIDP, or multifocal CIDP)? Yes No
Have you had a failed or poor response to either immunoglobulin therapy or corticosteroid therapy? Yes No
Do you have Hepatitis B, Hepatitis C or HIV? Yes No
Have you ever taken riliprubart? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Jorge E. Cabrera
jec2273@cumc.columbia.edu